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Amiotrophic Lateral Sclerosis (ALS) is a devastating neurodegenerative disease due to loss of motor 
neurons (MN). Recently, oligodendroglia have been implicated in the pathogenesis of ALS. 
Oligodendrocytes are severely affected during disease and their degeneration has been shown to 
precede MN death in the mutant SOD1 mouse model. As a consequence, oligodendrocyte precursor 
cells (OPCs) rapidly react with increased proliferation, but fail to replace degenerating 
oligodendrocytes. The differentiation capacity of OPCs is also impaired, resulting in the presence of 
immature and dysfunctional oligodendrocytes, unable to provide MN with trophic and metabolic 
support (Lee Y et al. 2012 Nature; Kang SH et al. 2013 Nat Neurosci). Restoring oligodendrocyte 
function and promoting OPC maturation thus emerge as interesting approaches for retard MN 
degeneration. An important regulator of OPC differentiation and myelination is the membrane P2Y-
like receptor GPR17, that is specifically expressed in OPCs in transition to pre-oligodendrocytes, but 
not in mature cells. We have shown that prevention of the physiological GPR17 downregulation at 
late OPC stages through forced receptor over-expression results in delayed cell maturation (Fumagalli 
M et al. 2015 Glia). Accordingly, GPR17 over-expression has been described in several mouse model 
of CNS degeneration characterized by remyelination failure (Fumagalli M et al. 2016 
Neuropharmacol). The involvement of GPR17 has never been studied in the context of ALS 
pathology.  
Here, we used western-blot to analyse GPR17 espression in parallel to the mature oligodendrocyte 
marker MBP in the SOD1G93A mouse ALS model. Spinal cord lumbar tracts of SOD1G93A mice 
at different disease stages, ie, before disease onset (Post-Natal Day, PND 30), at disease onset (PND 
90) and at later disease stages (PND 120) were compared with age-matched controls. We also 
examined the metabolic support function of oligodendrocytes by analyzing MCT1, a lactate 
transporter expressed by these cells. Data showed that the expression of MBP and MCT1 are reduced 
in lumbar spinal cord of late stage SOD1G93A mice. Reduced levels of MCT1 were also detected in 
presymptomatic PND30 mice. Of note, GPR17 expression was found to be up-regalated both at early 
and late disease stages. 
The demonstration that GPR17 is altered in ALS suggests that its dysregulation may be involved in 
the blockade of OPC differentiation contributing to disease development, and that it could represent 
an adequate new target for therapeutic intervention in ALS.  
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